Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Half of 2016 Biotech IPOs Positive At Mid-Year; 2015 Success Rate Sours

Executive Summary

It hasn't been easy for biopharmaceutical firms to go public in the US during 2016, but as of the end of June the scrutiny seems to be paying off – at least for investors in half of this year's first-half initial public offerings.

You may also be interested in...



Biopharma IPOs In 2016: Fewer Offerings, Better Returns As Firms Adjust To Market Realities

The number of US biopharma IPOs during the first 11 months of 2016 – 29 companies went public – is less than half of the 2015 total of 62, but stock performance has improved as investors focus on quality.

Efficiency Bows To Scrutiny: '90s Drug Development Timelines Have Doubled

The time it takes to get a new drug candidate through clinical trials and onto the market has almost doubled since the late 1990s – but timescales for discovering new drug candidates haven't changed over the past 15 years.

Case Studies: How Three Public Companies Financed R&D In A Tough Market

The market for public offerings by biopharma companies is tough, but Corbus Pharmaceuticals, Loxo Oncology and Novavax used three different strategies to raise cash from new and existing shareholders.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC096854

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel